Baycip 250 Tablet (Ciprofloxacin 250mg)
Baycip 500 Tablet (Ciprofloxacin 500mg)
Buy Baycip 250mg/500mg Tablet generic drug of Ciprofloxacin online at low price from most trusted website to cure Bacterial infections. Get all detail regarding this medicine like the review, use, side effect, dosage (missed/over), composition, substitutes, precautions, manufactured by Bayer Zydus Pharma, how long does last, how it works and many more. You can also get speedy delivery in UK, USA, Australia, France, China.
Baycip (ciprofloxacin hydrochloride) Tablets are synthetic broad-spectrum antimicrobial agents for oral administration. Ciprofloxacin hydrochloride, USP. A fluoroquinolone, is the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7-(1-piperazinyl)-3- quinolinecarboxylic acid.it is used for the Bacterial infections.this medication is the composition of Ciprofloxacin(250mg/500mg), it is an active Ingredient.this tablet is available in various strength: 250mg and 500mg
Baycip is indicated for the treatment of uncomplicated and complicated infections caused by ciprofloxacin susceptible pathogens.
Acute Exacerbation of Chronic obstructive airway disease, empyema, Acute bronchitis, lung abscess, infected bronchiectasis, cystic fibrosis and pneumonia, sinusitis and mastoiditis.
Acute pyelonephritis, complicated urinary tract infections, recurrent UTI and infections caused by the multi-resistant organism.
Infected wounds and postoperative infections caused by gram-negative organisms such as Enterobacteriaceae and pseudomonas aeruginosa and resistant staphylococci.
Septicaemia, bacteremia, and infections in the immunocompromised host
Intraabdominal abscess, peritonitis, cholangitis, and cholecystitis.
Severe pelvic infections caused by susceptible organisms.
Typhoid including carrier stage and resistant salmonella typhi infections.
Since Ciprofloxacin achieves adequate tissue concentration in bone, it is useful in the management of acute and chronic osteomyelitis.
Uncomplicated Gonococcal infections including those caused by beta-lactamase strains chancroid caused by H.ducreyi. Consideration should be given to applicable official guidance on the appropriate use of antibacterial agents.
The proper detail about how long does last is provided on the tablet strip. In one strip ten pills are available. This medicine is Store protected from light.
This medication should be administered orally to adults as described in the dosage guidelines.
The determination of dosage for any particular sufferer must take into consideration the severity and nature of the infection, the susceptibility of causative organisms, the integrity of the sufferer's host-defense works, and the status of hepatic function and renal function.
The duration of treatments depends upon the severity of the infection. The usual time is 7 to 14 days; however, for severe and complicated infection more prolonged therapy may be required.
This medicine should be administered at least 2 hours before or 6 hours after magnesium/ aluminum antacid, or sucralfate, didanosine buffered /chewable tablets or pediatric powder for oral solution, other highly buffered drugs, or other products containing iron or zinc and calcium.
*used in conjunction with metronidazole Generally, this medication should be continued for at least two days after the symptoms of infection have disappeared, except for inhalational anthrax (post-exposure)
In the clinical trial, a pediatric sufferer with moderate to serious infection was initiated on 6 to 10 mg/g L.V. every 8 hours and allowed to switch to oral therapy (10 to 20 mg/kg every hour). At the discretion of the physician. -complicated Urinary Tract or pyelonephritis (sufferer from 1 to 17 years of age): 10 mg/kg to 20 mg/kg (maximum 750 mg per dose; not to exceed even in patients weighing >51 kg) every 12 hours for 10-21* days.
* The physician determined the total duration of therapy for complicated urinary tract infection and pyelonephritis in the clinical trial. The men duration of treatment was 11 days (range 10 to 21 days).
Generic Ciprofloxacin is eliminated primarily by renal excretion; however, the drug is also metabolized and partially cleared through the biliary system of the liver and the intestine. These option pathways of drug elimination appear to compensate for the reduced renal excretion in patients with renal impairment. Nonetheless, some modification of dosage is suggested, particularly for patients with severe renal dysfunction. The following table provides dosage recommended for use in patients with renal impairment.RECOMMENDED STARTING AND MAINTENANCE DOES FOR PATIENTS WITH IMPAIRED RENAL FUNCTION
|CREATININE Clearance (mL/min)||Dose|
|>50||see usual dosage|
|30-50||250-500 mg q 12 h|
|5-29||250-500 mg q 18 h|
|Patients on hemodialysis Or peritoneal dialysis||250-500 mg q 24 h (after dialysis)|
When the serum creatinine concentration is known, the following formula may be used to estimate creatinine clearance.
Men: Creatinine clearance (mL/min) = Weight (kg)*(140-age) 72* serum creatinine (mg/dL)
Women: 0.85 * the value calculated for men.
Minor side effects are as follows
Major side effects are as follow.
Severe infection and /or infections due to Gram-positive or anaerobic bacteria, this pill should be used in combination with an appropriate antibacterial agent
This medication is not recommended for treatment of pneumococcal infections due to inadequate efficacy against Streptococcus pneumoniae.
Fluoroquinolone-resistant Neisseria gonorrhoeae isolates may cause genital tract infection. In genital tract infections thought or known to be due to N. gonorrhea, it is particularly important to obtain local detail on the prevalence of resistance to ciprofloxacin and to confirm susceptibility based on laboratory testing.
As with medicinal products in its class, Baycip 250 mg drug has been shown to cause arthropathy in weight-bearing joints of immature animals. The analysis of available safety data from this medicine use in patients less than 18 years of age, the main of whom had cystic fibrosis, did not disclose any evidence of drug-related cartilage or articular damage. The use of this drug for an indication other than the treatment of acute pulmonary exacerbation of cystic fibrosis caused by pseudomonas aeruginosa infection (aged 5-17 years), and for the use in inhalational anthrax (post-exposure) was not studied. For other indications clinical experience is limited.
In some instances, hypersensitivity and allergic reactions may occur following a single dose. A physician should be informed immediately. Anaphylactic/anaphylactoid situations in very rare instances can progress to a life-threatening shock, in some cases after the first administration, in these cases, generic medication ciprofloxacin has to be discontinued, and medical treatment is required.
In the event of serious and persistent diarrhea during or after treatment, a physician must be consulted since this symptom can hide a severe intestinal disease. Requiring immediate treatment. In such cases, this medicine must be discontinued and appropriate therapy initiated. Medicinal products that inhibit peristalsis are contraindicated.
There can be a normal increase in transaminases, alkaline phosphatase, or cholestatic jaundice, especially in patients with previous liver damage.
At any sign of tendinitis, a physician should be consulted, and the antibiotic treatment is discontinued. Care should be taken to keep the affected extremity at rest and avoid any inappropriate physical exercise.
Tendon rupture has been reported predominantly in the elderly or on prior systemic treatment with glucocorticoids.
This pill should be used with caution in patients with a history of tendon disorders related to quinolone treatment.
In epileptics and sufferer who have suffered from previous central nervous system (CNS) disorders (e.g., lowered convulsion threshold history of convulsion, reduced cerebral blood flow, altered brain structure, or stroke), convulsion should only be used where the benefits of treatment exceed the risks, since these patients are endangered because of possible CNS side effects.
In some instance, the CNS reactions occurred after the first administration of ciprofloxacin. In rare cases, depression can progress to self-endangering behavior. In these cases, this pill was had to be discontinued, and the physician should be informed immediately.
Ciprofloxacin has been shown to produce photosensitivity situation. Patients taking this drug should avoid direct exposure to excessive sunlight or UV-light. Therapy should be discontinued if photosensitization occurs.
Ciprofloxacin is known to be a moderate inhibitor of the CYP 4501A2 enzymes. Care should be taken when other medical products which are metabolized via the same enzymatic. The pathway is administered concomitantly. Increased plasma concentration associated with drug-specific side effects may be observed due to inhibition of their metabolic clearance by ciprofloxacin.
Ciprofloxacin in vitro power may meddle with the Mycobacterium spp. Culture test by concealment of mycobacterial development, causing false adverse outcomes in examples from patients from presently taking ciprofloxacin.
Baycip 500 mg must not be used in cases of hypersensitivity to active substance ciprofloxacin or other quinolone chemotherapeutics or the excipients (see section “List of excipient”). Concurrent administration of tizanidine and ciprofloxacin is contraindicated.
Since the safety of this medication in pregnant women has not been established and since, by animal studies, it is not improbable that the drug could cause damage to articular cartilage in the immature fetal organism, this drug must not be prescribed to pregnant women. Animal studies have not shown any proof of teratogenic effects.
This medicine is excreted in breast milk. Due to the potential risk of particular harm, this medicine should not be used during breastfeeding.
Baycip 250 mg solution might be utilized in youngsters for the second and third line treatment of entangled urinary tract diseases and pyelonephritis because of Escherichia coli and the treatment of intense pneumonic intensification of cystic fibrosis-related with pseudomonas aeruginosa.
Treatment should just be started after careful advantage/hazard assessment, because of conceivable antagonistic occasions identified with joints and/or encompassing tissues.
In sufferer with Renal Impairment, the dosage of this medication should be reduced based on creatinine clearance.
During clinical research with oral and parenteral ciprofloxacin, 49,038 patients received a course of the drug. Most of the adverse reported describe as only mild or moderate in severity, abated soon after the drug was discontinued because, and required to treat. Ciprofloxacin was discontinued of an adverse event in 1% of orally treated patients. The most much of the time revealed medicate related occasions, from clinical preliminaries of just for definitions, all measurement, all medication treatment spans, and for all signs of this tablet treatment were sickness (2.5%), the runs (1.6%), liver capacity tests irregular (1.3%), heaving (1%), and rash (1%).
Extra therapeutically vital occasions that happened in under 1% of Ciprofloxacin patients are recorded beneath.
a headache, abdominal pain/discomfort, foot pain, pain, pain in extremities, injection sites reaction.
palpitation, ventricular ectopy, syncope, hypertension, atrial flutter, angina pectoris, myocardial infarction, cardiopulmonary arrest, cerebral thrombosis, phlebitis, tachycardia, migraine, hypertension.
restlessness, lightheadedness, insomnia, dizziness, nightmares, drowsiness, weakness, malaise, anorexia, phobia, depersonalization, depression, paresthesia, abnormal gait, grand mal convulsion.
painful oral mucosa, dysphagia, intestinal perforation,oral candidiasis, gastrointestinal bleeding, cholestatic jaundice, hepatitis.
amylase increase, lipase increase
joint stiffness, arthralgia or back pain, achiness, neck or chest pain, flare up to gout
interstitial, nephritis, renal failure, polyuria retention, urethral bleeding, vaginitis, acidosis, breast pain.
dyspnea, laryngeal or pulmonary edema, hiccough, hemoptysis, epistaxis, bronchospasm, pulmonary embolism
allergic reaction pruritus, photosensitivity/ phototoxicity reaction, flushing, fever, urticaria, chills, angioedema, edema of the face, neck, lips, conjunctivae or hands, hyperpigmentation, erythema nodosum, cutaneous candidiasis, sweating
blurred vision, decreased visual acuity, diplopia, eye pain, tinnitus, hearing loss, bad taste, chromatopsia
In a study, systemic exposure of tizanidine was significantly increased when the drug was given concomitantly with Ciprofloxacin. The hypotensive and sedative effect of tizanidine were also potentiated. Concomitant administration of Ciprofloxacin and tizanidine is contraindicated. As with some other quinolones, simultaneous administration of theophylline and prolongation its elimination half-life. This elevated serum concentrations of theophylline should be monitored and dosage adjustments made as appropriate.
Some quinolones, including generic Ciprofloxacin, have also been shown to interfere with the metabolism of caffeine. This may guide to reduced clearance of caffeine and a prolongation of its serum half-life. Concurrent administration of a quinolone, including this drug, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx chewable/buffered pills or pediatric powder, other highly buffered drugs, or product containing calcium, zinc or iron, may substantially decrease its absorption, resulting in serum and urine levels considerably lower than desired. Histamine H2-receptor antagonists appear to have to significant effect on the bioavailability of Ciprofloxacin. Altered serum levels of phenytoin have been reported in patients receiving concomitant Ciprofloxacin. The concomitant administration of generic Ciprofloxacin with the sulfonylurea glyburide has, on rare occasion, resulted in severe hypoglycemia. No severe effect was observed on the bioavailability of Ciprofloxacin.
Non-steroidal anti-inflammatory drugs in a combination of very high doses of quinolones have been shown to provoke convulsions in preclinical studies.
Colloidal Silicon Dioxide, Maize Starch, Microcrystalline Cellulose, Magnesium Stearate, crospovidone, Hydroxypropyl Methylcellulose 2910, polyethylene Glycol 4000, Titanium Dioxide.
What do you think about this product?